HJB - Your Trusted Biologics CDMO Partner

HJB, CDMO, biologics, HJB Bio, hjbbio, China CDMO, 杭州奕安济世, Just Bio, Just biotherapeutics, HJB bio, HJB China, Hangzhou HJB

HJB - Your Trusted Biologics CDMO Partner

Cn
Company News

13Mar, 2024

HJB’s Continuous Perfusion Biomanufacturing platform has achieved a breakthrough productivity of >8 g/L-day

HANGZHOU, CHINA - On January 26, 2024, HJB announced a breakthrough in its Highly Intensified Continuous Bioprocessing (HiCB) platform. By leveraging the in-house developed cell culture medium, ExcelPro CHOTM, HiCB has achieved an impressive maximum daily output of 8 g/L-day in intensified continuous perfusion, over a tenfold increase in productivity when compared to same cell line in traditional fed-batch platform. 

06Nov, 2023

HJB announced a new strategic partnership with Apextide

HANGZHOU, CHINA - On November 06, 2023, HJB announced a new strategic partnership with Hangzhou Apextide Bio-pharmaceutical Technology Company Limited (hereinafter referred to as "Apextide"). This strategic partnership will pursue the marketing and promotion of the APIs and DP manufacturing of oligonucleotide.

27Apr, 2023

HJB Congratulates SynerK on Completion of Subject Administration with Domestic New siRNA Drugs!

On 27th April, SynerK, an innovative biopharmaceutical company focusing on developing RNA-targeted therapeutics, announced that its Phase I clinical trial of the first small interfering RNA (siRNA) product under research has been completed with the first subject enrolled for dosing. Public data shows that this is the first domestic siRNA candidate drug against a specific target, which is involved in the clinical administration and treatment phase in subjects. SynerK owns the completely independent intellectual property right.


21Jul, 2022

The First Batch of siRNA Drug Filled Successfully | HJB Completes High Yield Filling of SynerK's siRNA Formulation.

Small interfering RNA (siRNA) drugs, as a hotspot in the development of small nucleic acid-based drugs, have been widely used for their high gene silencing efficiency, controllable adverse effects, and easy synthesis. Recently, HJB has also embraced the first siRNA formulation filling project, which was commissioned by SynerK, a leading company in siRNA technology, for the development of siRNA formulation prescriptions and filling work. During the project, the two parties cooperated and gave full play to SynerK's experience in the development and production of siRNA formulations and to HJB's experience in the development and filling of injectable liquid formulations. The technical team of HJB overcame many technical difficulties and challenges of siRNA formulation and completed the first batch of filling in one go, with a filling yield as high as 95%.


21Apr, 2022

Leveraging HJB’s highly productive continuous perfusion platform, client’s manufacturing process output was increased by > 8 folds and the process change was recently approved by NMPA.

31Mar, 2022

HJB Congratulates its partner BioneCure for receiving IND approval from U.S.FDA for BIO-106

HJB congratulates its partner BioneCure for receiving IND approval for BIO-106.

30Dec, 2021

HJB congratulates its client on an approval of CMC process change supplemental application filed to Chinese National Medical Products Administration (NMPA) in support of a late phase clinical trial in China.

HJB congratulates its client on an approval of CMC process change supplemental application filed to  NMPA in support of a late phase clinical trial in China.

21Aug, 2021

HJB Congratulates Kanova Biopharma on receiving IND approval for XKH001 from U.S.FDA

HJB Congratulates its partner Kanova Biopharma for receiving IND approval from U.S.FDA for XKH001, a humanized monoclonal antibody for the treatment of autoimmune disease.